The role of radiotherapy in multimodal treatment of pancreatic carcinoma

Citations of this article
Mendeley users who have this article in their library.

This article is free to access.


Pancreatic ductal carcinoma is one of the most lethal malignancies, but in recent years a number of positive developments have occurred in the management of pancreatic carcinoma. This article aims to give an overview of the current knowledge regarding the role of radiotherapy in the treatment of pancreatic ductal adenocarcinoma (PDAC). The results of meta-analyses, phase III-studies, and phase II-studies using chemoradiotherapy and chemotherapy for resectable and non-resectable PDAC were reviewed. The use of radiotherapy is discussed in the neoadjuvant and adjuvant settings as well as in the locally advanced situation. Whenever possible, radiotherapy should be performed as simultaneous chemoradiotherapy. Patients with PDAC should be offered entry into clinical trials to identify optimal treatment results. © 2010 Brunner and Scott-Brown; licensee BioMed Central Ltd.




Brunner, T. B., & Scott-Brown, M. (2010, July 8). The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiation Oncology.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free